MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML

Abstract Background Oral azacitidine improves survival in patients with AML in first complete remission who are not candidates for allogeneic transplantation. Most favorable-risk AML patients harbor molecular markers enabling sensitive measurable residual disease (MRD) monitoring. While MRD is a wel...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Noa Hurvitz, Irina Amitai, Ilana Levy Yurkovski, Ariella Tvito, Yishai Ofran, Tzvika Porges, Ofir Wolach, Adi Sherban, Noa Gross Even-Zohar, Vladimir Vainstein, Arnon Haran, Shlomzion Aumann, Robert Mikhelashvili, Avraham Frisch, Boaz Nachmias
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Springer 2026-05-01
Cyfres:	Annals of Hematology
Pynciau:	Acute myeloid leukemia Maintenance Oral azacitidine Measurable residual disease Onureg
Mynediad Ar-lein:	https://doi.org/10.1007/s00277-026-07054-5
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!